Unveiling a Breakthrough: Arvinas’ ARV-102 Takes Bold Strides in the Fight Against Parkinson’s
Arvinas, Inc. has revealed promising results from its experimental drug ARV-102, indicating a potential breakthrough in Parkinson’s treatment. ARV-102, a PROTAC drug,
